R-PR Launches Nasacort In The UK

17 March 1997

- Rhone-Poulenc Rorer has launched Nasacort aqueous nasal spray(triamcinolone acetonide) in the UK. The corticosteroid is indicated for the treatment of both seasonal and perennial allergic rhinitis in adults and children. The cost to the UK National Health Service is L8.00 ($12.83) per pack, with a recommended once-daily dose of two sprays per nostril, which can be reduced to one spray per nostril after one week, once symptoms come under control, it says.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight